Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO4PVE)

• Drug Name: Apraclonidine Drug Info
• Synonyms: Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine

Indication

Disease Entry	ICD 11	Status	REF
Intra ocular pressure reduction	9C40	Approved	[1]

• Therapeutic Class: Antiglaucomic Agents
• Cross-matching ID:
  PubChem CID: 2216
  ChEBI ID: CHEBI:2788
  CAS Number: CAS 66711-21-5
  TTD Drug ID: DMO4PVE

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[4]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[5]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[3]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[6]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[7]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[8]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[9]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[10]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7117).
• [2] Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents.
• [3] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [4] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [5] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [6] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [7] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [8] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [9] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [10] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [11] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.